ovarian cancer

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.

Allarity Therapeutics received USPTO notice of allowance for stenoparib DRP® companion diagnostic patent, providing exclusivity through 2039.

PMV Pharmaceuticals appoints Laurie Stelzer as Board Chair effective June 2026, succeeding Rich Heyman. Transition occurs amid ongoing clinical trials for ovarian cancer treatment.

Epitopea appoints Dr. Lisa Butterfield, immuno-oncology expert, to Scientific Advisory Board to advance RNA-based cancer immunotherapies.

Incyclix Bio raises $5M from Hatteras Venture Partners for Phase 1/2 trial of INX-315, targeting therapy-resistant breast and ovarian cancers.

Zentalis Pharmaceuticals granted 36,000 stock options at $2.57/share to two new hires under Nasdaq inducement rules, vesting over four years.

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.

PMV Pharmaceuticals reports 50% response rate for ovarian cancer drug rezatapopt, but faces funding pressure with cash runway extending only to Q2 2027.